Fundamental Analysis of DENALI THERAPEUTICS INC(NASDAQ:DNLI) stock

Fundamental Rating

DNLI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. DNLI has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, DNLI is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

DNLI had negative earnings in the past year.

DNLI had a negative operating cash flow in the past year.

In the past 5 years DNLI reported 4 times negative net income.

DNLI had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

DNLI has a better Return On Assets (-12.59%) than 88.21% of its industry peers.

DNLI has a better Return On Equity (-14.09%) than 90.09% of its industry peers.

		Industry Rank	Sector Rank
ROA	-12.59%
ROE	-14.09%
ROIC	N/A

ROA(3y)-18.54%

ROA(5y)-17.38%

ROE(3y)-25.19%

ROE(5y)-23.88%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

DNLI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

DNLI does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, DNLI has more shares outstanding

DNLI has more shares outstanding than it did 5 years ago.

DNLI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 11.11 indicates that DNLI is not in any danger for bankruptcy at the moment.

The Altman-Z score of DNLI (11.11) is better than 86.84% of its industry peers.

There is no outstanding debt for DNLI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	11.11

ROIC/WACCN/A

WACC9.13%

2.3 Liquidity

DNLI has a Current Ratio of 13.65. This indicates that DNLI is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of DNLI (13.65) is better than 87.69% of its industry peers.

DNLI has a Quick Ratio of 13.65. This indicates that DNLI is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of DNLI (13.65) is better than 87.86% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	13.65
Quick Ratio	13.65

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

DNLI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.46%, which is quite impressive.

DNLI shows a strong growth in Revenue. In the last year, the Revenue has grown by 204.61%.

Measured over the past years, DNLI shows a very strong growth in Revenue. The Revenue has been growing by 20.67% on average per year.

EPS 1Y (TTM)58.46%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-14.67%

Revenue 1Y (TTM)204.61%

Revenue growth 3Y-0.52%

Revenue growth 5Y20.67%

Revenue growth Q2Q-100%

3.2 Future

The Earnings Per Share is expected to grow by 23.95% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 14.37% on average over the next years. This is quite good.

EPS Next Y-152.52%

EPS Next 2Y-47.18%

EPS Next 3Y-23.38%

EPS Next 5Y23.95%

Revenue Next Year-72.41%

Revenue Next 2Y-24.5%

Revenue Next 3Y-10.1%

Revenue Next 5Y14.37%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

DNLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year DNLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

DNLI's earnings are expected to decrease with -23.38% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-47.18%

EPS Next 3Y-23.38%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for DNLI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

DENALI THERAPEUTICS INC

NASDAQ:DNLI (5/8/2024, 2:20:53 PM)

18.89

+2.04 (+12.11%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.69B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-12.59%
ROE	-14.09%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.29

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	13.65
Quick Ratio	13.65
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)58.46%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-152.52%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)204.61%

Revenue growth 3Y-0.52%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

DENALI THERAPEUTICS INC (DNLI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens